Genitourinary Cancers

Durvalumab in combination with guadecitabine was tolerable and led to a PFS benefit in patients with checkpoint inhibitor-naive ccRCC.

Wenxin (Vincent) Xu, MD, shares recent updates in the treatment of renal cell carcinoma, including insights into ongoing research and trials within the space.

Elizabeth Plimack, MD, MS, FASCO, recaps the discussion with key takeaways on recent updates in bladder cancer.

Wenxin (Vincent) Xu, MD, discusses the evolving landscape of systemic therapy in RCC, sharing how he makes treatment decisions amid the changing treatment space.

Marijo Bilusic, MD, PhD, discusses combination regimens under investigation for patients with non–clear cell renal cell carcinoma.

Focusing on belzutifan, Laurence Albigès, MD, PhD, reviews data from the LITESPARK-005 clinical trial, and Martin H. Voss, MD, discusses the ongoing LITESPARK-011 trial.

Experts on advanced RCC discuss the CONTACT-03 trial evaluating atezolizumab plus cabozantinib following immune checkpoint inhibitor treatment in patients with inoperable disease.

Jaime R. Merchán, MD, discusses the current roles for immunotherapy and TKIs in patients with renal cell carcinoma.

Wenxin (Vincent) Xu, MD, highlights research in renal cell carcinoma, spotlighting developments and updates in patients with non-clear cell disease.

Wenxin (Vincent) Xu, MD, on evolving systemic therapy and the utilization of biomarkers in the treatment of renal cell carcinoma.

Experts on bladder cancer discuss exciting new agents and treatment strategies and where they can potentially fit into urothelial cancer treatment paradigms.

Focusing on metastatic urothelial carcinoma, the panel discusses the role of chemotherapy and outlines treatment sequencing approaches.

Wenxin (Vincent) Xu, MD, discusses treatment decision-making in patients with renal cell carcinoma.

David A. Braun, MD, PhD, provides clinical insights on factors that influence treatment decisions in the second line and beyond for patients with advanced clear cell RCC.

Focusing on the LITESPARK-003 and LITESPARK-024 trials, Laurence Albigès, MD, PhD, discusses novel doublet regimens under investigation in the first-line setting in advanced renal cell carcinoma.

Evan Y. Yu, MD, provides insights on treatment approaches for patients with metastatic urothelial carcinoma in the second line and beyond.

The expert panel discusses how treatment strategies change based on cisplatin eligibility and the role of maintenance therapy in metastatic urothelial carcinoma.

I-Chia (Daniel) Liu, MD, discusses surgical and local control outcomes following short-course radiation therapy and chemotherapy for rectal cancer.

Medical oncologists provide clinical insights on managing adverse events associated with IO-TKI and IO-IO regimens in patients with advanced renal cell carcinoma.

The expert panel reacts to 55-month follow-up data from CheckMate 9ER assessing nivolumab plus cabozantinib in patients with newly diagnosed advanced RCC.

Prolonged duration from neoadjuvant SCRT to surgery did not increase the risk of poor mesorectum specimen quality or post-operative morbidity in rectal cancer.

Brian I. Rini, MD, FASCO, shares the importance of the FDA approval of belzutifan in patients with advanced renal cell carcinoma.

GU medical oncologists offer their impressions of recent updates in the metastatic urothelial carcinoma space, focusing on CheckMate 901 and EV-302.

Neeraj Agarwal, MD, FASCO, provides a comprehensive overview of recent data in metastatic urothelial carcinoma, highlighting the CheckMate 901 and EV-302 studies.

Wenxin (Vincent) Xu, MD, discusses the factors he takes into account when sequencing treatment options for patients with metastatic renal cell carcinoma.